With the above aspects in mind, we used chronic myeloid leukemia cells, K562/DoxDR2, K562/DoxDR3, K562/ABCG2CL4, and K562/ABCG2CL10, with moderate to high expression levels of drug transporters (Figure 3) since one can expect relatively high expression levels of ABCB1 and ABCG2 in the BBB [38]. The gene discussed is ABCB1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.